0.85
-0.0029(-0.34%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.86 |
| Day High | 0.89 |
| Day Low | 0.82 |
| 52-Week High | 3.06 |
| 52-Week Low | 0.55 |
| Volume | 117,647 |
| Average Volume | 209,027 |
| Market Cap | 8.72M |
| PE | -0.76 |
| EPS | -1.13 |
| Moving Average 50 Days | 0.84 |
| Moving Average 200 Days | 1.03 |
| Change | -0 |
If you invested $1000 in Predictive Oncology Inc. (POAI) 10 years ago, it would be worth $0.04 as of August 18, 2025 at a share price of $0.853. Whereas If you bought $1000 worth of Predictive Oncology Inc. (POAI) shares 5 years ago, it would be worth $34.4 as of August 18, 2025 at a share price of $0.853.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Predictive Oncology Issues Shareholder Letter: Well Financed to Support Expanded U.S. Availability and E.U. Launch of ChemoFx® and Pursuit of Other High-Value AI-Driven Drug Discovery and Development Opportunities
GlobeNewswire Inc.
Jul 15, 2025 1:00 PM GMT
$10 million securities purchase agreement provides efficient and flexible funding in support of strategic multi-million dollar growth initiatives Discussions underway to expand adoption of ChemoFx in the U.S. and accelerate initial launch in Europe
Predictive Oncology Announces $10M Share Purchase Agreement in Partnership with Yorkville Advisors to Advance AI-Driven Drug Discovery and Repurposing
GlobeNewswire Inc.
Jul 08, 2025 1:00 PM GMT
PITTSBURGH, July 08, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery, announced today that it has entered into a standby equity purchase agreement (“SEPA”) with YA II PN, LTD, an investment fun
Predictive Oncology Develops Functional 3D Organoid Models Exclusively for Labcorp
GlobeNewswire Inc.
Jun 12, 2025 12:30 PM GMT
Models provide highly relevant species-specific data, predict in vivo drug clearance/transport, and support preclinical analysis of cancer therapiesPITTSBURGH, June 12, 2025 (GLOBE NEWSWIRE) -- Predictive Oncology Inc. (NASDAQ: POAI), a leader in A